Quarter | Prior | Estimate | Actual | Surprise | |
---|---|---|---|---|---|
Q3 2019 After-Hours | EPS: REV: | 0.23 117.781M | |||
Q2 2019 After-Hours | EPS: REV: | 0.27 113.466M | |||
Q1 2019 After-Hours | EPS: REV: | 0.25 111.854M | |||
Q4 2018 After-Hours | EPS: REV: | 0.28 114.168M | 0.12 105.34M | ||
Q3 2018 After-Hours | EPS: REV: | 0.27 113.588M | 105.34M | 0.23 117.781M | 11.81% |
Q2 2018 After-Hours | EPS: REV: | 0.26 113.888M | 0.23 107.24M | 0.27 113.466M | 17.39% 5.81% |
Q1 2018 After-Hours | EPS: REV: | 0.22 110.087M | 0.18 103.98M | 0.25 111.854M | 38.89% 7.57% |
Q4 2017 After-Hours | EPS: REV: | 0.21 112.107M | 0.21 105.45M | 0.28 114.168M | 33.33% 8.27% |
Q3 2017 After-Hours | EPS: REV: | 0.21 111.752M | 0.27 113.588M | ||
Q2 2017 After-Hours | EPS: REV: | 0.43 136.999M | 0.23 108M | 0.26 113.888M | 13.04% 5.45% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- 'We See Room For Further Outperformance': CyberArk Analysts Bullish After Q4 Earnings Beat
- KeyBanc: Diebold's New CEO Executing Well, But Long-Term Growth Remains A Concern
- Dana Inc. Beats Q4 And Full-Year 2018 Expectations
- Analysts Aren't Cutting CBS Despite Earnings Miss
- The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings